GlassScriptPhysician profile
Jay R Lentzner
NPI 1982884904
$18,804.90
in general payments reported to CMS, 2019-2025
31 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $456 · 2021: $2,909 · 2022: $3,764 · 2023: $4,752 · 2024: $4,781 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,411.64 |
| Education | $146.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,424.01 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $2,146.86 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $2,094.26 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,737.90 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,444.48 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,065.18 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,059.14 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $1,056.32 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $828.61 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $804.09 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $724.11 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $512.06 | 2019-2024 | Trintellix |
| Allergan, INC. | $464.99 | 2019-2020 | |
| Axsome Therapeutics, INC. | $464.15 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $425.26 | 2021-2024 | Qelbree, Qelbree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $371.20 | 2022-2024 | Azstarys |
| Almatica Pharma LLC | $303.46 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $139.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $135.67 | 2024 | Cobenfy |
| Bausch Health US, LLC | $107.05 | 2022-2024 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $106.33 | 2023-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $66.13 | 2022-2024 | Quviviq |
| Sage Therapeutics, LLC | $55.26 | 2024 | |
| Neuronetics, INC. | $46.70 | 2022 | |
| Indivior INC. | $45.05 | 2019-2023 | Perseris |
| Noven Therapeutics, LLC | $42.26 | 2023-2024 | Xelstrym |
| Eisai INC. | $39.26 | 2021 | |
| Brainsway USA INC | $36.39 | 2019 | |
| Neos Therapeutics, LP | $22.91 | 2021 | |
| Sun Pharmaceutical Industries INC. | $21.85 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.81 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Lentzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.